Abstract: In one aspect, nutraceutical compositions, methods of preparation and methods of use comprise a nutraceutical composition comprising an antimicrobial hevamine A-related protein from Momordica balsamina alone or in combination with one or more nutraceutical ingredients. In another aspect, a method of preventing or treating a microbial infection in a plant comprises applying an effective amount of a composition containing the hevamine A-related protein to a whole plant, plant part, or media in which the plant is growing. In a further aspect, the present application provides a transgenic plant stably transformed with a polynucleotide encoding the hevamine A-related protein.

Abstract: The present application relates to a compositions and methods comprising or expressing a HEVAR or MOMO30 protein derived from Momordica balsamina. The HEVAR or MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for treating or preventing viral infections, particularly those caused by coronaviruses, such as SARS-CoV-2.

Abstract: In one aspect, nutraceutical compositions, methods of preparation and methods of use comprise a nutraceutical composition comprising an antimicrobial hevamine A-related protein from Momordica balsamina alone or in combination with one or more nutraceutical ingredients. In another aspect, a method of preventing or treating a microbial infection in a plant comprises applying an effective amount of a composition containing the hevamine A-related protein to a whole plant, plant part, or media in which the plant is growing. In a further aspect, the present application provides a transgenic plant stably transformed with a polynucleotide encoding the hevamine A-related protein.

Abstract: The present application relates to a compositions and methods comprising or expressing a hevamine A-related MoMo30 protein from Momordica balsamina. The MoMo30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients, and comprises an amino acid sequence of SEQ ID NO: 4. The MoMo30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating microbial infections by HIV, SARS-CoV-2 and other enveloped viruses, as well as other microorganisms comprising cell surface proteins containing glycan residues, such as mannose.

Abstract: The present application relates to a compositions and methods comprising or expressing a MOMO30 protein derived from Momordica balsamina. The MOMO30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients and comprises the amino acid sequence of SEQ ID NO: 1. The MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating viral infections by HIV and other enveloped viruses.

Abstract: The present application relates to a compositions and methods comprising or expressing a HEVAR or MOMO30 protein derived from Momordica balsamina. The HEVAR or MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for treating or preventing viral infections, particularly those caused by coronaviruses, such as SARS-CoV-2.

Abstract: The present application relates to a compositions and methods comprising or expressing a HEVAR or MOMO30 protein derived from Momordica balsamina. The HEVAR or MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for treating or preventing viral infections, particularly those caused by coronaviruses, such as SARS-CoV-2.

Abstract: The present application relates to a compositions and methods comprising or expressing a HEVAR or MOMO30 protein derived from Momordica balsamina. The HEVAR or MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for treating or preventing viral infections, particularly those caused by coronaviruses, such as SARS-CoV-2.

Abstract: The present application relates to a compositions and methods comprising or expressing a MOMO30 protein derived from Momordica balsamina. The MOMO30 protein is about 30 kDa in size, binds coronavirus S protein, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to coronavirus spike (S) protein, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by a coronavirus or alleviating symptoms in coronavirus infected patients and comprises the amino acid sequence of SEQ ID NO: 1. The MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating viral infections by coronaviruses and others.

Abstract: The present application relates to a compositions and methods comprising or expressing a MOMO30 protein derived from Momordica balsamina. The MOMO30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients and comprises the amino acid sequence of SEQ ID NO: 1. The MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating viral infections by HIV and other enveloped viruses.

Abstract: The invention relates to an antiviral product based on Aframomum Melegueta, which is virolytic, virostatic and water-soluble, for the treatment and prevention of Acquired Immunodeficiency Syndrome (AIDS) and variants thereof. It is produced as follows: The Aframomum Melegueta leaf after collection is dried naturally and reduced to a fine powder. The dried powder is macerated in water sterilized with 100% methanol. The solution is then passed through a filter with a diameter of 0.45 micron and produces a sterilized antiviral, virolytic, virostatic and water-soluble product. The different experiments show that the product: has an antiviral activity, has toxic and destructive effects on cells infected by the AIDS virus, inactivates the virus and appears to be virostatic, is water-soluble, is not complex and has molecules less than 10,000 Da in size and shows resistance to the protease treatment.

Abstract: The invention relates to an antiviral product based on Momordica Balsamina, which is virolytic, virostatic and water-soluble, for the treatment and prevention of Acquired Immunodeficiency Syndrome (AIDS) and variants thereof. It is produced as follows: The Momordica Balsamina leaf after collection is dried naturally and reduced to a fine powder. The dried powder is macerated in water sterilized with 100% methanol. The solution is then passed through a filter with a diameter of 0.45 micron and produces a sterilized antiviral, virolytic, virostatic and water-soluble product. The different experiments show that the product: has an antiviral activity, has toxic and destructive effects on cells infected by the AIDS virus, inactivates the virus and appears to be virostatic, is water-soluble, is not complex and has molecules less than 10,000 Da in size and shows resistance to the protease treatment.

Abstract: The invention relates to an antiviral product based on Cyperus Articulatus, which is virolytic, virostatic and water-soluble, for the treatment and prevention of Acquired Immunodeficiency Syndrome (AIDS) and variants thereof. It is produced as follows: The Cyperus Articulatus leaf after collection is dried naturally and reduced to a fine powder. The dried powder is macerated in water sterilized with 100% methanol. The solution is then passed through a filter with a diameter of 0.45 micron and produces a sterilized antiviral, virolytic, virostatic and water-soluble product. The different experiments show that the product: has an antiviral activity, has toxic and destructive effects on cells infected by the AIDS virus, inactivates the virus and appears to be virostatic, is water-soluble, is not complex and has molecules less than 10,000 Da in size and shows resistance to the protease treatment.